A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine Used for Sedation During Elective Awake Fiberoptic Intubation

The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine versus placebo used for sedation during elective awake fiberoptic intubation.

Study Overview

Status

Completed

Detailed Description

An awake fiberoptic intubation is indicated for any patient with an anticipated difficult airway because of their anatomy, airway trauma, morbid obesity, or unstable cervical spine injuries. An awake fiberoptic intubation in a non-sedated patient can be extremely stimulating, uncomfortable, and unpleasant. The clinician must focus on maintaining spontaneous breathing, hemodynamic stability, and the patient's comfort. The term "awake" fiberoptic intubation is used to distinguish this procedure from fiberoptic intubations performed under general anesthesia. Although patients may be sedated for "awake" fiberoptic intubation, they need to be responsive and capable of maintaining their own airway without assistance. Vital components of a successful awake fiberoptic intubation include an anesthesiologist experienced in this technique, adequate topicalization of the airway, and a sedated yet cooperative subject.

Benzodiazepines, combined with opioid, are commonly used for anxiolysis and/or analgesia during awake fiberoptic intubations.

Dexmedetomidine has sympatholytic, sedative, analgesic, and anxiolytic effects that attenuate the catecholamine response to perioperative stress. Dexmedetomidine sedates patients by decreasing sympathetic activity and the level of arousal. Further more, dexmedetomidine has been found to facilitate a decrease in salivary secretion, a desirable effect during fiberoptic intubations.

An estimated 100 subjects (50 DEX, 50 PBO) scheduled for an elective awake fiberoptic intubation because of a potentially difficult airway will be randomized prior to intubation at approximately 18 investigative sites.

Study Type

Interventional

Enrollment (Actual)

124

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35294
        • University of Alabama at Birmingham
    • California
      • Loma Linda, California, United States, 92354
        • Loma Linda University Medical Center
    • Florida
      • Miami, Florida, United States, 33136
        • University of Miami Jackson Memorial Hospital
    • Illinois
      • Chicago, Illinois, United States, 60612
        • University of Illinois Medical Center at Chicago
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • University of Kansas Medical Center
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Mayo Clinic Rochester
    • New York
      • New York, New York, United States, 10016
        • New York University Medical Center
      • New York, New York, United States, 10029
        • The Mount Sinai School of Medicine
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • The Cleveland Clinic Foundation
      • Columbus, Ohio, United States, 43210-1228
        • The Ohio State University Medical Center
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18103-6296
        • LeHigh Valley Hospital
    • South Carolina
      • Charleston, South Carolina, United States, 29425
        • Medical University of South Carolina
    • Texas
      • Dallas, Texas, United States, 75216
        • VA North Texas Health Care System
      • Houston, Texas, United States, 77030
        • The University of Texas
      • Houston, Texas, United States, 77030
        • The University of Texas Medical School at Houston
      • Temple, Texas, United States, 76508
        • Scott and White Memorial Hospital
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53295
        • VA Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Adult (≥18 years of age);
  2. American Society of Anesthesiologists (ASA) score I - IV inclusive;
  3. Male or female. If female, subject is non-lactating and is either:

    1. Not of childbearing potential, defined as post-menopausal for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy.
    2. Of childbearing potential but is not pregnant at time of baseline and is practicing one of the following methods of birth control: oral or parenteral contraceptives, double-barrier method, vasectomized partner, or abstinence from sexual intercourse.
  4. Requiring awake fiberoptic (oral or nasal) intubation because of anticipated difficult airway. Subjects must meet at least one of the criteria listed below:

    Criteria for Assessing Difficult Airways

    i. History of difficult intubation

    ii. Anticipated difficult airway

    1. Prominent protruding teeth
    2. Small mouth opening
    3. Narrow mandible
    4. Micrognathia
    5. Macroglossia
    6. Short, muscular neck
    7. Very long neck
    8. Limited neck extension
    9. Congenital airway anomalies
    10. Obesity
    11. Known airway pathology
    12. Known airway malignancy
    13. Upper airway obstruction

    iii. Trauma

    1. Face
    2. Upper airway
    3. Cervical spine

    iv. Anticipated difficult mask ventilation

    v. Severe risk of aspiration

    vi. Respiratory failure

    vii. Severe hemodynamic instability

  5. Subject (or subject's legally authorized representative) must voluntarily sign and date the informed consent.

Exclusion Criteria:

  1. Previous exposure to any experimental drug within 30 days prior to study drug administration;
  2. Central nervous system (CNS) disease with an anticipated increased intracranial pressure or cerebrospinal fluid (CSF) leak;
  3. Uncontrolled seizure disorder and/or known psychiatric illness that could confound a normal response to sedative treatment;
  4. Presence of acute alcohol intoxication;
  5. Current (within 14 days of study entry) treatment with an α2-agonist or antagonist;
  6. Subject for whom benzodiazepines, dexmedetomidine or other α2-agonists are contraindicated;
  7. Subject received an IV or oral (PO) opioid within one hour or intramuscularly within four hours of the start of study drug administration;
  8. Subject has acute unstable angina, laboratory confirmed acute myocardial infarction within the past 6 weeks, heart rate <50 bpm, systolic blood pressure (SBP) <90 mmHg, or complete heart block unless they have a pacemaker.
  9. Subject has elevated serum glutamic pyruvate aminotransferase/alanine transaminase (SGPT/ALT) and/or Serum glutamic oxaloacetic transaminase/ aspartate aminotransferase (SGOT/AST) values of ≥2 times the upper limit of normal (ULN).
  10. Subject has any other condition or factor which, in the Investigator's opinion, might increase the risk to the subject.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Dexmedetomidine
Dexmedetomidine 1 mcg/kg load for 10 minutes and Dexmedetomidine Maintenance (0.7 mcg/kg/hr) for 15 min
Placebo Comparator: Placebo (PBO)
Placebo load for 10 min and Placebo maintenance for 15 min

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The percentage of subjects requiring rescue midazolam to achieve and/or maintain proper sedation levels throughout the study drug infusion
Time Frame: At baseline and 15 minutes after starting study drug (prior to topicalization), and every 3 minutes thereafter throughout study drug infusion, at the end of topicalization, and prior to administration of any rescue medication.
Sedation levels (Ramsay Sedation Scale [RSS] score ≥2 [Patient is cooperative, oriented and tranquil])
At baseline and 15 minutes after starting study drug (prior to topicalization), and every 3 minutes thereafter throughout study drug infusion, at the end of topicalization, and prior to administration of any rescue medication.

Secondary Outcome Measures

Outcome Measure
Time Frame
Total dose of rescue midazolam required to achieve and/or maintain target sedation levels
Time Frame: During the drug maintenance (i.e, Approximately 15 minutes after starting study drug).
During the drug maintenance (i.e, Approximately 15 minutes after starting study drug).
Percentage of subjects requiring additional rescue medications other than midazolam to achieve and/or maintain target sedation levels
Time Frame: During the drug maintenance (i.e, Approximately 15 minutes after starting study drug).
During the drug maintenance (i.e, Approximately 15 minutes after starting study drug).
Anesthesiologist assessment of ease of subject care
Time Frame: Immediately following discontinuation of study drug, prior to the scheduled surgery/procedure (Approximately 24 hours).
Immediately following discontinuation of study drug, prior to the scheduled surgery/procedure (Approximately 24 hours).
Subject recall and satisfaction assessed 24 hours post study drug
Time Frame: At the end of the 24-Hour Follow-Up Period
At the end of the 24-Hour Follow-Up Period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2006

Primary Completion (Actual)

January 1, 2007

Study Completion (Actual)

March 1, 2007

Study Registration Dates

First Submitted

October 2, 2006

First Submitted That Met QC Criteria

October 2, 2006

First Posted (Estimate)

October 4, 2006

Study Record Updates

Last Update Posted (Estimate)

July 24, 2015

Last Update Submitted That Met QC Criteria

July 23, 2015

Last Verified

July 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe